Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Trisalus Life Sciences
TLSI · NASDAQ · Surgical & Medical Instruments & Apparatus
Trisalus Life Sciences (TLSI) · oqro.io/stocks/TLSI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
A Trisalus Life Sciences director paid $112K out of pocket for Trisalus Life Sciences shares. It was the first purchase in 6 months. Shares held went up 34% with this purchase.
Their largest buy since 2024Traded May 15 · filed 3 days later
Since the trade −15.3% · S&P 500 +0.1% · to Nov 16
A Trisalus Life Sciences director paid $152K out of pocket for Trisalus Life Sciences shares. 4 other people at Trisalus Life Sciences bought some too, in the same month. Shares held went up 69% with this purchase.
Since the trade −15.3% · S&P 500 +0.1% · to Nov 16
The CEO of Trisalus Life Sciences paid $103K out of pocket for Trisalus Life Sciences shares. 4 other people at Trisalus Life Sciences bought some too, in the same month.
Since the trade −15.3% · S&P 500 +0.1% · to Nov 16
A Trisalus Life Sciences director paid $25K out of pocket for Trisalus Life Sciences shares. 4 other people at Trisalus Life Sciences bought some too, in the same month. Shares held went up 16% with this purchase.
Since the trade −15.3% · S&P 500 +0.1% · to Nov 16
The CFO of Trisalus Life Sciences paid $17K out of pocket for Trisalus Life Sciences shares. 4 other people at Trisalus Life Sciences bought some too, in the same month.
13 open-market purchases and 18 open-market sales by insiders of TLSI between Feb 3, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 10, 2026.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
Mats Wahlstrom, Director, Nov 12, 2026, about $112K. Bought 2 days after the company's previous earnings release on 2026-11-10Form 4
Bryan F. Cox, Chief of Research, Oct 5, 2026, about $1.3K. Sold 36 days before the company's next earnings release on 2026-11-10Form 4
Richard Marshak, Chief Commercial Officer, Oct 5, 2026, about $1.4K. Sold 36 days before the company's next earnings release on 2026-11-10Form 4
Jennifer Stevens, Chief Regulatory Officer, Oct 5, 2026, about $1.4K. Sold 36 days before the company's next earnings release on 2026-11-10Form 4
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
Richard Marshak, Chief Commercial Officer, May 15, 2026, about $1.4K. Sold 3 days after the company's previous earnings release on 2026-05-12